权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MKP5 allostery in MAPK regulation and signaling in the heart

MKP5 变构在心脏 MAPK 调节和信号传导中的作用

基本信息

批准号：
10375784
负责人：
Anton M Bennett
金额：
$ 62.03万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-01-18 至 2025-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10375784
关键词：
Adopted Allosteric Site Binding Binding Sites Biology CRISPR/Cas technology Cardiac development Catalysis Catalytic Domain Cells Cellular biology Chemicals Clinical Complex Coupled Crystallization Data Development Disease Effectiveness Fingerprint Generations Genetic Goals Heart Heart failure Intervention Kinetics Knock-in Knock-in Mouse MAPK phosphatase MAPK8 gene Mediating Mitogen-Activated Protein Kinases Modeling Molecular Morbidity - disease rate Mus Outcome Pathway interactions Pharmaceutical Preparations Pharmacology Phosphoric Monoester Hydrolases Physiological Play Protein Kinase Interaction Proteomics Regulation Resolution Role Signal Transduction Site Specificity Structure Therapeutic Tissues Transforming Growth Factors United States Work biophysical techniques coronary fibrosis druggable target experimental study fibrogenesis genetic approach in vivo inhibitor insight mortality mouse genetics mutant novel operation p38 Mitogen Activated Protein Kinase phosphatase inhibitor phosphoproteomics pressure small molecule structural biology therapeutic target transcriptomics

项目摘要

ABSTRACT The catalytic activity and specificity of the mitogen-activated protein kinase (MAPK) phosphatases (MKPs) is governed through their ability to interact with the MAPKs. The MKPs set the fidelity and kinetics of MAPK signaling by regulating, in a spatially distinct manner, both the magnitude and duration of MAPK activity. However, these regulatory mechanisms alone are insufficient to explain the complexity of MKP/MAPK- mediated signaling. This is exemplified by the observation that inactivation of MKPs deliver unique, and in some cases, non-obvious physiological and pathophysiological outcomes that has led to the realization that MKPs represent valuable therapeutic targets for the treatment of certain diseases. We have found that MKP5, which directly dephosphorylates p38 MAPK and JNK, is involved in the development of cardiac fibrosis, a serious sequalae that precedes heart failure. Mice lacking MKP5 are protected from the development of cardiac fibrosis and heart failure in a model of pressure overload. A high throughput small molecule screen identified a first-in-class inhibitor of MKP5. Resolution of the co-crystal structure of the inhibitor in complex with MKP5 revealed that the inhibitor bound to an allosteric site on MKP5. We hypothesize that the MKP5 allosteric site represents an additional mode of MKP5 regulation that governs signaling specificity and that this allosteric site represents the “Achilles heel” of MKP5 for small molecule targeting. The broad goal of this work is two-fold. First, we will define the molecular basis for how the allosteric site regulates MKP5 catalysis and MAPK signaling. Second, whether disruption of the allosteric site produces outcomes in a disease context that provide proof-of-concept that if successfully “drugged” this site represents a platform for development of first-in-class MKP inhibitors. We will execute the specifics of these two broad goals through three specific aims. Aim 1, will employ structural biology and biophysical approaches to elucidate the structural determinants and binding mechanisms conferred by the MKP5 allosteric site to determine how this site regulates MKP5 catalysis and MAPK binding. A co-complex between MKP5 and p38 MAPK will be obtained to define how p38 MAPK modulates MKP5 through the allosteric site. In Aim 2, the effects of mutants in the MKP5 allosteric site on MAPK signaling will be determined by generating knockin cells harboring MKP5 allosteric site mutants using CRISPR-Cas approaches. The specificity of the MKP5 allosteric site to “fine-tune” MAPK-mediated signaling will be determined using non-biased phosphoproteomic and transcriptomic approaches. In Aim 3, the effects of targeting the MKP5 allosteric site in cardiac fibrosis and heart failure will be determined through the generation of a novel MKP5 allosteric site mutant knock-in mouse. These studies will define a new mode of operation for MKP5 that will provide information on the actions of the allosteric site at the atomic level. How the MKP5 allosteric site impacts physiological signaling and the validity of the allosteric site as a “druggable” target in disease therapeutics will be defined.

摘要